Name of License: VA Offer Of Exclusive Patent License To exci, Corp.
Summary: Notice is hereby given that the Department of Veterans Affairs (VA), Office of Research and Development, Technology Transfer Program, intends to grant to exci, Corp., 415 U St. NW, Washington, DC 20001, USA an exclusive license to U.S. Patent Nos. 9,320,907 and 10,201,703, U.S. Patent Application Nos. 16/229,530, 16/549,743, 63/007,596 and 63/080,904, and International Patent Application No. PCT/US2019/047864, associated with VA Invention Disclosure numbers 10-049, 2020-129 and 2020-376, respectively titled, “Integrated surface stimulation device for pain management and wound therapy”, “Flexatrode”, and, “AFTIDerm”.
Tech Name:
Integrated surface stimulation device for pain management and wound therapy
Dates: Comments must be received on or before December 24, 2020.
Address: Send comments to Mr. Ryan Davis, Technology Transfer Specialist, Office of Research and Development (10X2TT), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (202) 632-7554 (this is not a toll-free number), [email protected].
For Further Information Contact: Send comments to Mr. Ryan Davis, Technology Transfer Specialist, Office of Research and Development (10X2TT), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (202) 632-7554 (this is not a toll-free number), [email protected].
Supplementary Information: The Federal Government’s patent rights in this invention are assigned to the US Government as represented by the Department of Veterans Affairs. It is in the public interest to license this invention as exci, Corp. has submitted a complete and sufficient application for a license. The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 15 days from the date of this published Notice, the Department of Veterans Affairs Office of Research and Development, Technology Transfer Program receives written evidence and argument which establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.